Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure

American Heart Journal

Volumn 149, Issue 5, 2005, Pages 938.e1-938.e7

  Blanchet, Martine ^a   Sheppard, Richard ^a   Racine, Normand ^a   Ducharme, Anique ^a   Curnier, Daniel ^a   Tardif, Jean Claude ^a   Sirois, Pierre ^c   Lamoureux, Marie Catherine ^a   De Champlain, Jacques ^b   White, Michel ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; IRBESARTAN; LISINOPRIL; METOPROLOL; NORADRENALIN; PERINDOPRIL; PLACEBO; RAMIPRIL;

ADULT; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYNAMIC EXERCISE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REST; SYMPTOM; TREATMENT OUTCOME;

EID: 21144453604     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.11.011     Document Type: Article

References (21)

1. J.N. Cohn, and G. Tognoni A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N. Engl. J. Med. 345 2001 1667 1675
2. J.J. McMurray, J. Ostergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
3. R.S. McKelvie, J.L. Rouleau, and M. White Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure Eur. Heart J. 24 2003 1727 1734
4. G. Hamroff, S.D. Katz, and D. Mancini Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure Circulation 99 1999 990 992
5. M. Guazzi, P. Palermo, and G. Pontone Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure Am. J. Cardiol. 84 1999 1038 1043
6. P.A. Ades, M.L. Waldmann, and E.T. Poehlman Exercise conditioning in older coronary patients. Submaximal lactate response and endurance capacity Circulation 88 1993 572 577
7. A.I. Larsen, T. Aarsland, and M. Kristiansen Assessing the effect of exercise training in men with heart failure; comparison of maximal, submaximal and endurance exercise protocols Eur. Heart J. 22 2001 684 692
8. M. Blanchet, A. Ducharme, and N. Racine Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol) Am. J. Cardiol. 92 2003 548 553
9. J. Myers, N. Buchanan, and D. Walsh Comparison of the ramp versus standard exercise protocols J. Am. Coll. Cardiol. 17 1991 1334 1342
10. M. Tonkon, N. Awan, and I. Niazi A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group Int. J. Clin. Pract. 54 2000 11 18
11. Heart Failure Society of America (HFSA) practice guidelines HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches J. Card. Fail. 5 1999 357 382
12. M. Guazzi, G. Melzi, and G.C. Marenzi Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction Clin. Pharmacol. Ther. 65 1999 319 327
13. J.F. Jasmin, A. Calderone, and T.K. Leung Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan Cardiovasc. Res. 58 2003 621 631
14. D.G. Kiely, R.I. Cargill, and B.J. Lipworth Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade Cardiovasc. Res. 30 1995 875 880
15. L. Dalla Libera, B. Ravara, and A. Angelini Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure Circulation 103 2001 2195 2200
16. R.S. McKelvie, S. Yusuf, and D. Pericak Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study Circulation 100 1999 1056 1064
17. N. Ohkubo, H. Matsubara, and Y. Nozawa Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism Circulation 96 1997 3954 3962
18. D.T. Dinh, A.G. Frauman, and C.I. Johnston Angiotensin receptors: distribution, signalling and function Clin. Sci. (Lond) 100 2001 481 492
19. M. Stoll, U.M. Steckelings, and M. Paul The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells J. Clin. Invest. 95 1995 651 657
20. L. Barki-Harrington, L.M. Luttrell, and H.A. Rockman Dual inhibition of beta adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo Circulation 108 2003 1611 1618
21. R. Latini, S. Masson, and I. Anand Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure Circulation 106 2002 2454 2458